How Epstein's 'great friend' came back to biotech

Also: White House says it's "done" with vaccines. MAHA begs to differ ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

March 14, 2026 Check out STAT+

Sponsored By

We're running a limited-time offer to get 50% off an annual STAT+ subscription. Becoming a STAT+ member supports our newsroom directly, and helps our commitment to uncompromising watchdog journalism — plus gives you special access to events, data tools, and more. Thanks for reading.

Illustration: Camille MacMillin/STAT; Source photo: Department of Justice STAT+ | A top biotech VC quietly helped Epstein's 'great friend' make a comeback Boris Nikolic, who unwound his venture fund in 2019 after disclosure of Epstein ties, returns to biotech investing as revelations emerge of his past connections. By Damian Garde Andrew Harnik/Getty Images STAT+ | White House says it's 'done' with vaccines. MAHA begs to differ As Trump political advisers try to move on from vaccine policy debates, MAHA movement insiders push back, calling RFK Jr. supporters vital to GOP's success. By Daniel Payne and Chelsea Cirruzzo LINDA BARTLETT / NATIONAL CANCER INSTITUTE / SCIENCE PHOTO LIBRARY STAT+ | Cancer cells can 'barf' proteins onto their cell surface. That may create new targets for immunotherapies A protein normally inside cells was found on the surface of tumors and successfully targeted for treatment in mice. By Angus Chen STAT+ | As controversial decisions mount, FDA shuns public advisory meetings Controversial drug decisions mount as FDA reduces public advisory meetings. Industry leaders say the adcomms can add transparency to the approval process. By Lizzy Lawrence STAT+ | 5 lessons from Vinay Prasad's turbulent tenure at the FDA Prasad, a public critic of FDA laxity, learned that being a regulator is different than being a talking head. By Matthew Herper STAT+ | The FDA is targeting telehealth marketing of GLP-1 drugs. Who's prescribing them? As FDA warning letters target telehealth marketers of GLP-1 drugs, questions arise about the role played by nationwide medical groups prescribing the drugs. By Katie Palmer Opinion: I'm a medical student. RFK Jr. is right about medical school and preventive care Preventive and lifestyle-based approaches continue to receive little emphasis in medical education. By Lauren Rice

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Weekend Reads? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser